VectivBio Holding AG (VECT)
Chart Events
Performance Outlook
| Previous Close | 6.30 |
| Open | 6.42 |
| Bid | 2.17 x 1000 |
| Ask | 7.50 x 900 |
| Day's Range | 5.40 - 6.23 |
| 52 Week Range | 2.74 - 16.75 |
| Volume | |
| Avg. Volume | 15,923 |
| Market Cap | 223.552M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.58 |
| Earnings Date | Nov 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.75 |
- GlobeNewswire
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV. Company management will also be participating in one-on-one investor meetin
- GlobeNewswire
VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
Arena Pharmaceuticals and Actelion veteran brings deep industry experience as VectivBio prepares for key upcoming catalystsBASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Patrick Malloy as Senior Vice President, Investor Relations and Strategic Communications. Mr. Malloy’s two decades of in
- GlobeNewswire
VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023 Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase 3 Data Management to Host Conference Call Today at 8.00 a.m. ET BASEL, Switzerland, April 07, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceut
